Blog / Archives
Clinical Diagnostics Part 1: a sector poised for growth
Many of the issues coming out of the healthcare reform discussion: rising medical costs, Medicare budget, need for better clinical outcomes, push for biogenerics have caused concern among...
Complete Genomics
Complete Genomics 2/18/10 Molecular Diagnostics and Genomics “Powering large-scale human genome studies”. Private Company Summary Complete Genomics(CGI) provides high quality,...
ISIS and GENZ meet trial goal; ISIS stock sells off
Clinical Profile concerns spur a big sell-off : ISIS shares down 14.6% to $9.40 on volume of 10.6M shares The Mipomersen Phase 3 study in patients with Heterozygous Familial Hypochesterolemia, a...
New Coverage: genomics and diagnostics-Genomic Health(GHDX)
Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development...
Microfluidics (MFLU.OB-$0.90) -a leader in advanced nano-material processing for a variety of industries
Microfluidics (MFLU.OB-$0.90) -a leader in advanced, nano-material, processing for a variety of industries A turn-around play with value characteristics This is a "heads-up" on a special report that...
Life Science Sector Performance: ETF’s and Funds Feb 12 mos.YTD
In a volatile sell-off day involving tech stocks, the biotech world was relatively calm. Despite good news on corporate earnings and a GDP with an annual 5.7% annual growth, investors chose to take...
Biomedical stocks beat the bleak
Large Cap biomedical stocks held firm on another volatile but down day in the market driven by a host of macro and fundamental factors: earnings, Davos, Greece,China, politics, Bernanke...
Gilead Sciences revenues and profits up sharply on antiviral drugs
Gilead (GILD) shares were up 6% to $47.75 after the close as the Company announced record sales and earnings. Full Year total Revenues were $7.01B up 31% over 2008. Full Year Non-GAAP EPS were $3.06...
Amgen Earnings just OK; January effect for BIO topped out
AMGN-Top line revenue slowing One of the largest biotech companies reported earnings within estimates with full year 2009 EPS of $4.91 up 8% on Revenue of $14.6B down 2%.2010 Total Revenue is...
Waxman Power Play to squeeze Biotech for “biogenerics”
It is hard to believe but the Obama administration wants to open up a new political front at the last minute to squeeze the biotechnology industry after everyone thought the 12 year protection from...